BCAX

Bicara Therapeutics Inc.
CAPPED RATING

Bicara Therapeutics Inc. (BCAX) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Revisions (F). The rating has held at D+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
B-
Factor Score 2.9 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.5
EV / EBITDA -0.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -60.9%
Price Return 12M -31.6%
Catalyst Signal 0.00
Market Cap $647.3M
TTM Revenue N/A
Price / Sales N/A
ROE -54.2%

Historical Factor Score Progression

Held D+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D+ (1.7) B- (2.9) C- (2.0) F (0.0) D+ (1.8)
2026-11-10 C+ (2.5) D+ (1.7) B- (2.9) D+ (1.8) F (0.0) D+ (1.8)
2026-11-03 C+ (2.5) D+ (1.7) B- (2.9) D+ (1.6) F (0.0) D+ (1.8)
2026-10-27 C+ (2.5) D+ (1.7) B- (3.0) C- (1.9) C+ (2.6) C (2.3)
2026-10-20 C+ (2.5) D+ (1.7) B- (3.0) C- (2.1) C+ (2.6) C (2.4)
Page 1 of 4